Sivik Global Healthcare LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sivik Global Healthcare LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the biotechnology company's stock, valued at approximately $1,216,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. MassMutual Private Wealth & Trust FSB raised its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. grew its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. UMB Bank n.a. lifted its position in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Sarepta Therapeutics during the third quarter worth approximately $59,000. Institutional investors own 86.68% of the company's stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company's stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded up $0.12 during trading on Monday, hitting $113.84. 248,044 shares of the company's stock were exchanged, compared to its average volume of 820,748. The company has a market cap of $10.87 billion, a PE ratio of 91.06 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The stock's 50 day moving average price is $122.80 and its two-hundred day moving average price is $126.94.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Raymond James reiterated an "outperform" rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, January 27th. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Piper Sandler decreased their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. Finally, HC Wainwright reiterated a "sell" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.